Nice follow up post Cityslicker. Just a reminder, apabetalone is only one of thousands of BET inhibitors in their library. They have several follow on compounds ready to go into clinical development. Some may be improved versions of apabetalone for same indications. Some may be of differing BET protein or bromodomain specificity that are better suited for different indications.

Don't overlook the fact that this is the first company to take a BET inhibitor through Phase 3. No doubt in my mind that Resverlogix and Zenith are the world leaders in this field. Sell or license the apabetalone compound for a boatload of Benjamins, but keep the compound library and IP to further develop and capitalize on their huge head start in the bright future of bromodomain epigenetic drugs. Same logic for Zenith and ZEN-3694.

BDAZ